Hypertriglyceridemia — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for hypertriglyceridemia. 158 active patents protecting 6 drugs from 5+ originators. First major cliff: 2029. Daily refresh.

6
Approved drugs
158
Active US patents
59/100
Avg vulnerability
—
Annual revenue covered

Originators in Hypertriglyceridemia

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Amarin Pharms 122 patents Pfizer Inc. 21 patents Merck & Co. 10 patents AstraZeneca 4 patents Salix 1 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating hypertriglyceridemia. Each bar = one year. Y-axis scaled to peak year (74 patents).

7
26
6
27
3
29
74
30
50
33
5
37
7
38
6
41

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Vascepa
ICOSAPENT ETHYL
 Amarin Pharms 122 50 — 2027-05-31
Caduet
Amlodipine Besylate
 Pfizer Inc. 16 63 — 2029-10-05
Zocor
simvastatin
 Merck & Co. 10 70 — 2026-10-11
Lipitor
Atorvastatin Calcium
 Pfizer 5 61 — 2037-06-07
Epanova
OMEGA-3-CARBOXYLIC ACIDS
 AstraZeneca 4 48 — 2026-12-20
Tricor (Micronized)
FENOFIBRATE
 Salix 1 62 — 2033-05-31

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
7326708 Zocor other 80 2026-10-11
7326708 Zocor other 80 2026-10-11
7326708 Zocor other 80 2026-10-11
7326708 Zocor other 80 2026-10-11
7326708 Zocor other 80 2026-10-11
7326708 Zocor other 80 2026-10-11
11925704 Lipitor method of use 75 2037-06-07
10799487 Caduet method of use 75 2038-01-23
12440441 Caduet method of use 75 2041-02-24
12226528 Caduet method of use 75 2041-02-24

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
9050309 Epanova composition of matter 4 2033-01-04
8298554 Vascepa formulation 31 2030-04-29
8298554 Vascepa formulation 36 2030-04-29
10350171 Caduet formulation 42 2038-06-14
10350171 Caduet formulation 42 2038-06-14
10350171 Caduet formulation 42 2038-06-14
9623001 Vascepa method of use 45 2033-06-28
9623001 Vascepa method of use 45 2033-06-28
10668042 Vascepa method of use 45 2033-06-28
10786478 Vascepa method of use 45 2033-06-28

Related